Analysed TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) News Sources
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
22-10-2026
yahoo.com
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
26-10-2026
yahoo.com
Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative
01-10-2026
yahoo.com
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
14-10-2026
yahoo.com
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
15-10-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
15-10-2026
yahoo.com
Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)
20-10-2026
yahoo.com
What is the current price of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)?
The current price of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) is $20.18.
TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) absolute price change since previous trading day?
The absolute price change of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) since the previous trading day is $-0.09.
TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) percentage price change since previous trading day?
The percentage price change of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) since the previous trading day is -0.444%.
What is the most recent average sentiment score for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)?
The most recent average sentiment score for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) is 54 out of 100.
What is the most recent average sentiment for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)?
The most recent sentiment for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) is .
SEC-8K** Filing Available For TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.